Description: Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Home Page: www.sensorion.com
375, rue du Professeur Joseph Blayac
Montpellier,
34080
France
Phone:
33 4 67 20 77 30
Officers
| Name | Title |
|---|---|
| Ms. Nawal Ouzren | CEO & Director |
| Ms. Catherine Leveau | Head of Investor Relations & Communication |
| Dr. Geraldine Honnet M.D. | Chief Medical Officer |
| Ms. Christine Le Bec | Head of CMC Gene Therapy |
| Ms. Stephanie Filipe | Head of the Project Management Office |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9724 |
| Price-to-Sales TTM: | 6.5758 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 38 |